Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease
Monoclonal antibodies to tumor necrosis factor (TNF) have become a mainstay of the
therapeutic armamentarium in inflammatory bowel disease (IBD) over the last 15 years.
Although highly effective, primary and secondary nonresponse are common and associated
with poor clinical outcomes and significant costs. Multiple clinical, genetic and
immunopharmacological factors may impact the response to anti-TNFs. Early stratification of
IBD patients by the expected risk of therapeutic failure during the induction and maintenance …
therapeutic armamentarium in inflammatory bowel disease (IBD) over the last 15 years.
Although highly effective, primary and secondary nonresponse are common and associated
with poor clinical outcomes and significant costs. Multiple clinical, genetic and
immunopharmacological factors may impact the response to anti-TNFs. Early stratification of
IBD patients by the expected risk of therapeutic failure during the induction and maintenance …
Monoclonal antibodies to tumor necrosis factor (TNF) have become a mainstay of the therapeutic armamentarium in inflammatory bowel disease (IBD) over the last 15 years. Although highly effective, primary and secondary nonresponse are common and associated with poor clinical outcomes and significant costs. Multiple clinical, genetic and immunopharmacological factors may impact the response to anti-TNFs. Early stratification of IBD patients by the expected risk of therapeutic failure during the induction and maintenance phases of treatment may allow for treatment optimization and potentially optimal short- and long-term outcomes. The aim of this review is to summarize the current data concerning the potential predictors of therapeutic success and failure of anti-TNFs in IBD.
Sage Journals